HK Stock MarketDetailed Quotes

03681 SINOMAB BIO-B

Watchlist
  • 1.110
  • 0.0000.00%
Market Closed Dec 13 16:08 CST
1.21BMarket Cap-5.55P/E (TTM)

SINOMAB BIO-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q6)Jun 30, 2024
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
(FY)Dec 31, 2020
(Q6)Jun 30, 2020
(FY)Dec 31, 2019
Turnover
48.42%2.03M
--1.37M
--1.37M
----
----
--25.91M
----
----
----
----
Operating income
48.42%2.03M
1.37M
1.37M
25.91M
Cost of sales
-57.26%-1.48M
---943K
---943K
----
----
----
----
----
----
----
Operating expenses
-57.26%-1.48M
-943K
-943K
Gross profit
28.67%543K
422K
422K
Administrative expenses
31.86%-34.21M
-18.19%-97.62M
-48.31%-50.2M
38.09%-82.59M
-3.01%-33.85M
-85.25%-133.4M
34.32%-32.86M
-17.01%-72.01M
---50.03M
-584.13%-61.54M
Research and development expenses
17.55%-55.04M
24.93%-135.41M
18.73%-66.75M
9.41%-180.37M
8.73%-82.13M
-92.56%-199.11M
-88.18%-89.98M
51.76%-103.4M
---47.82M
-353.32%-214.34M
Operating interest expense
----
----
----
----
14.37%-2.14M
-140.94%-5.82M
-63.98%-2.5M
-3.34%-2.42M
---1.52M
---2.34M
Special items of operating profit
109.48%1.36M
63.79%-3.93M
36.09%-14.37M
-138.02%-10.84M
-278.31%-22.48M
-49.06%28.52M
-31.96%12.61M
2,782.34%55.98M
--18.53M
107.99%1.94M
Operating profit
33.28%-87.34M
13.61%-236.53M
6.90%-130.89M
3.56%-273.8M
-24.72%-140.6M
-132.99%-283.91M
-39.45%-112.74M
55.90%-121.85M
-80.84M
-242.87%-276.28M
Financing cost
-2.65%-3.29M
-32.69%-6.58M
---3.2M
---4.96M
----
----
----
----
----
----
Share of profits of associates
----
----
----
-25.81%-5.4M
-91.31%-3.19M
-474.16%-4.29M
---1.67M
---747K
----
----
Earning before tax
32.42%-90.62M
14.45%-243.11M
6.74%-134.1M
1.40%-284.16M
-25.69%-143.79M
-135.07%-288.19M
-41.52%-114.4M
55.63%-122.6M
-80.84M
-230.44%-276.28M
After-tax profit from continuing operations
32.42%-90.62M
14.45%-243.11M
6.74%-134.1M
1.40%-284.16M
-25.69%-143.79M
-135.07%-288.19M
-41.52%-114.4M
55.63%-122.6M
-80.84M
-230.44%-276.28M
Earning after tax
32.42%-90.62M
14.45%-243.11M
6.74%-134.1M
1.40%-284.16M
-25.69%-143.79M
-135.07%-288.19M
-41.52%-114.4M
55.63%-122.6M
-80.84M
-230.44%-276.28M
Profit attributable to shareholders
32.42%-90.62M
14.45%-243.11M
6.74%-134.1M
1.40%-284.16M
-25.69%-143.79M
-135.07%-288.19M
-41.52%-114.4M
55.63%-122.6M
-80.84M
-230.44%-276.28M
Basic earnings per share
38.46%-0.08
17.24%-0.24
13.33%-0.13
0.00%-0.29
-36.36%-0.15
-141.67%-0.29
-37.50%-0.11
63.64%-0.12
-0.08
-175.00%-0.33
Diluted earnings per share
38.46%-0.08
17.24%-0.24
13.33%-0.13
0.00%-0.29
-36.36%-0.15
-141.67%-0.29
-37.50%-0.11
63.64%-0.12
-0.08
-175.00%-0.33
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Audit Opinions
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
Auditor
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
--
Ernst & Young
(Q6)Jun 30, 2024(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021(FY)Dec 31, 2020(Q6)Jun 30, 2020(FY)Dec 31, 2019
Turnover 48.42%2.03M--1.37M--1.37M----------25.91M----------------
Operating income 48.42%2.03M1.37M1.37M25.91M
Cost of sales -57.26%-1.48M---943K---943K----------------------------
Operating expenses -57.26%-1.48M-943K-943K
Gross profit 28.67%543K422K422K
Administrative expenses 31.86%-34.21M-18.19%-97.62M-48.31%-50.2M38.09%-82.59M-3.01%-33.85M-85.25%-133.4M34.32%-32.86M-17.01%-72.01M---50.03M-584.13%-61.54M
Research and development expenses 17.55%-55.04M24.93%-135.41M18.73%-66.75M9.41%-180.37M8.73%-82.13M-92.56%-199.11M-88.18%-89.98M51.76%-103.4M---47.82M-353.32%-214.34M
Operating interest expense ----------------14.37%-2.14M-140.94%-5.82M-63.98%-2.5M-3.34%-2.42M---1.52M---2.34M
Special items of operating profit 109.48%1.36M63.79%-3.93M36.09%-14.37M-138.02%-10.84M-278.31%-22.48M-49.06%28.52M-31.96%12.61M2,782.34%55.98M--18.53M107.99%1.94M
Operating profit 33.28%-87.34M13.61%-236.53M6.90%-130.89M3.56%-273.8M-24.72%-140.6M-132.99%-283.91M-39.45%-112.74M55.90%-121.85M-80.84M-242.87%-276.28M
Financing cost -2.65%-3.29M-32.69%-6.58M---3.2M---4.96M------------------------
Share of profits of associates -------------25.81%-5.4M-91.31%-3.19M-474.16%-4.29M---1.67M---747K--------
Earning before tax 32.42%-90.62M14.45%-243.11M6.74%-134.1M1.40%-284.16M-25.69%-143.79M-135.07%-288.19M-41.52%-114.4M55.63%-122.6M-80.84M-230.44%-276.28M
After-tax profit from continuing operations 32.42%-90.62M14.45%-243.11M6.74%-134.1M1.40%-284.16M-25.69%-143.79M-135.07%-288.19M-41.52%-114.4M55.63%-122.6M-80.84M-230.44%-276.28M
Earning after tax 32.42%-90.62M14.45%-243.11M6.74%-134.1M1.40%-284.16M-25.69%-143.79M-135.07%-288.19M-41.52%-114.4M55.63%-122.6M-80.84M-230.44%-276.28M
Profit attributable to shareholders 32.42%-90.62M14.45%-243.11M6.74%-134.1M1.40%-284.16M-25.69%-143.79M-135.07%-288.19M-41.52%-114.4M55.63%-122.6M-80.84M-230.44%-276.28M
Basic earnings per share 38.46%-0.0817.24%-0.2413.33%-0.130.00%-0.29-36.36%-0.15-141.67%-0.29-37.50%-0.1163.64%-0.12-0.08-175.00%-0.33
Diluted earnings per share 38.46%-0.0817.24%-0.2413.33%-0.130.00%-0.29-36.36%-0.15-141.67%-0.29-37.50%-0.1163.64%-0.12-0.08-175.00%-0.33
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Audit Opinions --Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion
Auditor --Ernst & Young--Ernst & Young--Ernst & Young--Ernst & Young--Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Pharmaceutical Companies
Pharmaceutical Companies
Intraday-2.31%